Brief: Canbridge Pharmaceuticals Says HY Revenue RMB 34.7 Million
24/08/2022 10:20
Aug 24 (Reuters) - Canbridge Pharmaceuticals Inc 1228.HK :
* HY REVENUE 34.7 MILLION RMB VERSUS 12.2 MILLION RMB
* HY LOSS ATTIBUTABLE RMB249.0 MILLION VERSUS LOSS OF
RMB344.2
MILLION
Source text for Eikon: ID:nHKS1BSCkj
Further company coverage: 1228.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CANbridge Pharmaceuticals
See all newsChina's CANbridge Pharmaceuticals H1 revenue rises on Hunterase and Livmarli strength
Brief: CANbridge Pharmaceuticals Posts HY Loss of RMB37.1 MLN
Brief: Canbridge Pharmaceuticals Says Livmarli Obtains NHIA Reimbursement Approval In Taiwan For ALGS And PFIC
Brief: Canbridge Pharmaceuticals Initiates Registration And Launch Preparations For Gaurunning In North African Market
CANbridge Pharmaceuticals jumps as WuXi Biologics buys shares